Jeffrey Barrett: AAPS 2011 Profile - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Jeffrey Barrett: AAPS 2011 Profile


Jeffrey Barrett



Jeffrey Barrett

Jeffrey S. Barrett, PhD, is a Research Professor in the University of Pennsylvania School of Medicine and Director of the Laboratory for Applied PK/PD at the Children's Hospital of Philadelphia (CHOP). His research is focused on developing mathematical models to guide the design and analysis of both translational science experiments and clinical trials. These studies are pivotal to the development of new medicines and to improve our understanding of disease biology. Dr Barrett's group develops decision support tools that interface such models with hospital-based medical records systems to guide drug therapy in critically-ill children. Much of his effort has been focused in children with cancer where Dr Barrett works with colleagues at CHOP to a find cure for infant leukemia.

View Full Research Presentation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here